Sugi Predict

Sugi Predict / Compounds / SCHEMBL20162985

SCHEMBL20162985

SCHEMBL20162985

Cc1[nH]c2ncnc(N)c2c1-c1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 1/20 0.50
▸ MAP3K14 Q99558 1/20 0.50
▸ EGFR P00533 3/20 0.49
▸ SRC P12931 3/20 0.48
▸ ABL1 P00519 2/20 0.48
▸ KDR P35968 5/20 0.47
▸ TEK Q02763 3/20 0.47
▸ KIT P10721 2/20 0.47
▸ ADK P55263 6/20 0.46
▸ LCK P06239 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ DAPK3 O43293 1/20 0.43
▸ RIPK2 O43353 1/20 0.43
▸ FYN P06241 1/20 0.43
▸ YES1 P07947 1/20 0.43
▸ LYN P07948 1/20 0.43
▸ HCK P08631 1/20 0.43
▸ PDGFRB P09619 1/20 0.43
▸ FGR P09769 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23481367 0.84 PIK3CD (0.41) IKBKBMAP3K14EGFRSRCABL1
SCHEMBL20162699 0.82 SRC (0.48) IKBKBMAP3K14EGFRSRCABL1
SCHEMBL20175456 0.80 EGFR (0.46) IKBKBMAP3K14EGFRABL1KDR
SCHEMBL20162889 0.76 LOXL2 (0.41) KDRTEKKITFYNPDGFRB
SCHEMBL20162856 0.75 MAPT (0.44) IKBKBMAP3K14EGFRABL1ADK
SCHEMBL20162858 0.75 MAPT (0.44) IKBKBMAP3K14EGFRABL1ADK
SCHEMBL20173293 0.75 MAPT (0.44) IKBKBMAP3K14EGFRABL1ADK
SCHEMBL12675873 0.73 KDM4E (0.50) EGFRSRCABL1KDRTEK
SCHEMBL23452143 0.71 MAP3K14 (0.48) IKBKBMAP3K14SRCKITLCK
SCHEMBL12675874 0.70 KDM4E (0.47) EGFRSRCABL1KDRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612409-B2 Pyrrolopyrimidines as CFTR potentiators CYSTIC FIBROSIS FOUNDATION (US) 2026-04-28 — — US disclosed
EP-4424311-A2 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS Cystic Fibrosis Foundation (US) 2024-09-04 — — EP disclosed
EP-3541390-B1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUND (US) 2024-05-01 — — EP disclosed
US-20230250100-A1 Pyrrolopyrimidines as CFTR Potentiators CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. 2023-08-10 — — US disclosed
US-20230250100-A1 Pyrrolopyrimidines as CFTR Potentiators CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. 2023-08-10 — — US disclosed
US-20230250100-A1 Pyrrolopyrimidines as CFTR Potentiators CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. 2023-08-10 — — US disclosed
US-20210171534-A1 Pyrrolopyrimidines as CFTR Potentiators CYSTIC FIBROSIS FOUNDATION 2021-06-10 — — US disclosed
US-20200017512-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS PFIZER INC. 2020-01-16 — — US disclosed
US-20200017512-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS PFIZER INC. 2020-01-16 — — US disclosed
EP-3541390-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS Cystic Fibrosis Foundation Therapeutics Inc. (US) 2019-09-25 — — EP disclosed
US-20190225621-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION 2019-07-25 — — US disclosed
US-20190225621-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION 2019-07-25 — — US disclosed
US-10301315-B2 Pyrrolopyrimidines as CFTR potentiators CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2019-05-28 — — US disclosed
US-10301315-B2 Pyrrolopyrimidines as CFTR potentiators CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2019-05-28 — — US disclosed
WO-2018094137-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) 2018-05-24 — — WO disclosed
WO-2018094137-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) 2018-05-24 — — WO disclosed
US-20180141954-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2018-05-24 — — US disclosed
US-20180141954-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2018-05-24 — — US disclosed
US-20180141954-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2018-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171534-A1 Pyrrolopyrimidines as CFTR Potentiators CFTR, P2RX1, P2RX5 IKBKB 512/4885MAP3K14 3605/4885EGFR 1738/4885
US-20200017512-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CFTR, P2RX1, P2RX5 IKBKB 512/4885MAP3K14 3605/4885EGFR 1738/4885
US-20190225621-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CFTR, P2RX1, P2RX5 IKBKB 512/4885MAP3K14 3605/4885EGFR 1738/4885
US-20230250100-A1 Pyrrolopyrimidines as CFTR Potentiators CFTR, P2RX1, P2RX5 IKBKB 512/4885MAP3K14 3605/4885EGFR 1738/4885
US-12612409-B2 Pyrrolopyrimidines as CFTR potentiators CFTR, CLCN2, SLC26A3 IKBKB 911/4885MAP3K14 4134/4885EGFR 1493/4885
US-10301315-B2 Pyrrolopyrimidines as CFTR potentiators CFTR, P2RX1, P2RX5 IKBKB 506/4885MAP3K14 3711/4885EGFR 1861/4885
US-20180141954-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CFTR, P2RX1, P2RX5 IKBKB 506/4885MAP3K14 3711/4885EGFR 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.